Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Novartis South Africa (Pty) Ltd., Magwa Crescent West, Waterfall City, Jukskei View, Johannesburg, 2090
JALRAMET 50 mg/850 mg tablet.
JALRAMET 50 mg/1000 mg tablet.
| Pharmaceutical Form |
|---|
|
JALRAMET 50 mg/850 mg: yellow, ovaloid bevelled edge, film-coated tablet imprinted with “NVR” on one side and “SEH” on the other side. JALRAMET 50 mg/1000 mg: dark yellow, ovaloid bevelled edge, film-coated tablet imprinted with “NVR” on one side and “FLO” on the other side. |
JALRAMET 50 mg/850 mg: Each tablet contains 50 mg vildagliptin and 850 mg metformin hydrochloride.
JALRAMET 50 mg/1000 mg: Each tablet contains 50 mg vildagliptin and 1 000 mg metformin hydrochloride.
| Active Ingredient | Description | |
|---|---|---|
| Metformin |
Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. |
|
| Vildagliptin |
Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion by increasing the endogenous levels of these incretin hormones. The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). |
| List of Excipients |
|---|
|
JALRAMET 50 mg/850 mg: Hydroxypropyl cellulose, hypromellose, iron oxide yellow, magnesium stearate, polyethylene glycol, talc, titanium dioxide. JALRAMET 50 mg/1000 mg: Hydroxypropyl cellulose, hypromellose, iron oxide yellow, magnesium stearate, polyethylene glycol, talc, titanium dioxide. |
10, 30, 60, 120, 180 or 360’s tablets in PA / AI / PVC (polyamide / aluminium / polyvinylchloride) blisters with an aluminium foil backing.
Not all pack sizes may be marketed.
Novartis South Africa (Pty) Ltd., Magwa Crescent West, Waterfall City, Jukskei View, Johannesburg, 2090
JALRAMET 50 mg/850 mg tablet: 48/21.2/0729
JALRAMET 50 mg/1000 mg tablet: 48/21.2/0730
Namibia:
JALRAMET 50 mg/850 mg: 20/21.2/0126 NS2
JALRAMET 50 mg/1000 mg: 20/21.2/0127 NS2
Date of Registration of medicine: May 2019
| Drug | Countries | |
|---|---|---|
| JALRAMET | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
